Total
0
Shares
Medlab (ASX:MDC)- CEO, Sean Hall
CEO, Sean Hall
Source: Medlab
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Medlab Clinical (MDC) receives human ethics approval for Australian sites for its non-opioid pain medication, NanaBis
  • The approval is for a phase three cancer bone pain trial, which aims to be rolled out across Australia, the U.S. and the U.K.
  • Last year, NanaBis met all the primary and secondary endpoints for a clinical trial
  • On the market this afternoon, Medlab was up 3.13 per cent, trading at 16.5 cents per share

Medlab Clinical (MDC) have received human ethics approval for Australian sites for its NanaBis cancer bone pain phase three trial.

A well-known Australian Human Research Ethics Committee (HREC), Belberry, has granted approvals for two sites — Professor Stephen Clarke at GenesisCare in Sydney and Professor Phil Good at the Mater Hospital in Brisbane.

Notably, Professor Clarke was the private investigator in the March 2020 trials.

NanaBis is the company’s most advanced non-opioid pain medication using its NonoCelle platform.

The drug is gearing up for a global phase three trial involving Australia, the United Kingdom and the United States.

Last year, NanaBis met all the primary and secondary endpoints for a clinical trial, which included improvements in pain, increases in quality of life and opioid-sparing.

Medlab’s regulatory strategy is to meet the US Food and Drug Administration for cancer bone pain by 2024 and then undertake a marketing claims expansion trial
to seek secondary claims approval for cancer pain.

Now, the company is reviewing two other Australian Sites that may be included in this HREC approval.

On the market this afternoon, Medlab was up 3.13 per cent, trading at 16.5 cents per share at 1:25 pm AEST.

MDC by the numbers
More From The Market Herald
Dimerix (ASX:DXB) - Managing Director and CEO, Nina Webster

" Dimerix (ASX:DXB) expands DMX-200 study into Australia

Dimerix (DXB) has entered an agreement with the NHMRC Clinical Trials Centre at the University of Sydney to expand the CLARITY 2.

" ACCC scrambles to halt Virtus Health’s (ASX:VRT) purchase of Healius (ASX:HLS) IVF clinics

The ACCC has taken “a significant step” as it seeks an urgent injunction to stop Virtus Health’s (VRT) proposed acquisition of Adora Fertility
IDT Australia (ASX:IDT) - Chair, Alan Fisher

" IDT Australia (ASX:IDT) signs manufacturing deal with Monash University

IDT Australia (IDT) has entered a master services agreement and services order with Monash University.
Prescient Therapeutics (PTX) - CEO and MD, Steven Yatomi Clarke

" Prescient Therapeutics (ASX:PTX) to present new OmniCAR data at conference

Prescient Therapeutics (PTX) will present new results for its OmniCAR drug at the Cell & Gene Meeting on Mesa in California.